Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC a...
Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China
Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC at ASCO 2021 ( Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China )
16 Jul 2021
ASCO 2021: Precision and molecular reporting for prostate cancer
Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA
ASCO 2021: Precision and molecular reporting for prostate cancer ( Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA )
29 Jun 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethaso...
Prof Thierry Facon - Chu De Lille, Lille, France
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )
25 Jun 2021
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hod...
Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )
22 Jun 2021
GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL
Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlan...
GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL ( Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands )
15 Jun 2021
PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to pr...
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to preserve ovarian function ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
11 Jun 2021
Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial ...
Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA
Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )
10 Jun 2021
Adjuvant chemo following chemoradiation as treatment for locally advanced cervic...
Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia
Adjuvant chemo following chemoradiation as treatment for locally advanced cervical cancer compared to chemoradiation alone ( Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia )
10 Jun 2021
CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma
Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA
CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma ( Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA )
9 Jun 2021
Highlights from ASCO 2021
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Jun 2021
NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resect...
Dr Jonathan Spicer - McGill University, Montreal, Canada
NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC ( Dr Jonathan Spicer - McGill University, Montreal, Canada )
4 Jun 2021